StreetInsider.com News Articles

Neumora Therapeutics (NMRA) PT Lowered to $5 at Needham

Tue, 16 Jun 2026 07:13:10 -0400

(Updated - June 16, 2026 7:13 AM EDT)

Needham analyst Ami Fadia lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $5.00 (from $8.00) while maintaining a Buy rating.

The analyst commented: "NMRA will be discontinuing navacaprant development following the KOASTAL-2/3 readout which, did not meet the PE (MADRS) or the key SE (SHAPS). While disappointing, we are removing navacaprant related sales and costs from our model and incorporating the 35% workforce reduction (right-sizing to a mid-stage biotech) announced today, which will drive $10M in annualized savings (mgt expects to hit run-rate in 2027). This lowered our PT from $8 to

Neumora Therapeutics (NMRA) PT Lowered to $5 at Needham

Tue, 16 Jun 2026 07:13:10 -0400

(Updated - June 16, 2026 7:13 AM EDT)

Needham analyst Ami Fadia lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $5.00 (from $8.00) while maintaining a Buy rating.

Neumora Therapeutics (NMRA) PT Lowered to $7 at H.C. Wainwright

Tue, 16 Jun 2026 06:47:13 -0400

(Updated - June 16, 2026 6:47 AM EDT)

H.C. Wainwright analyst Douglas Tsao lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $7.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Neumora announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not meet the primary or key secondary endpoints and, as a result, the company is discontinuing development of the drug. The company will focus its attention on NMRA-898 (M4 PAM), NMRA-511 (V1a antagonist) and NMRA-215 (NRLP3 inhibitor). We were a bit surprised by the magnitude of

Neumora Therapeutics (NMRA) PT Lowered to $7 at H.C. Wainwright

Tue, 16 Jun 2026 06:47:13 -0400

(Updated - June 16, 2026 6:47 AM EDT)

H.C. Wainwright analyst Douglas Tsao lowered the price target on Neumora Therapeutics (NASDAQ: NMRA) to $7.00 (from $18.00) while maintaining a Buy rating.

Form 8-K Neumora Therapeutics, For: Jun 10

Mon, 15 Jun 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260615/26644641.html

Form 8-K Neumora Therapeutics, For: Jun 10

Mon, 15 Jun 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260615/26644641.html

Neumora Therapeutics (NMRA) Halted, News Pending

Mon, 15 Jun 2026 08:01:13 -0400

Neumora Therapeutics (NASDAQ: NMRA) Halted, News Pending

Neumora discontinues navacaprant after phase 3 trials fail primary endpoints

Mon, 15 Jun 2026 08:00:42 -0400

Neumora Therapeutics Inc. (NASDAQ: NMRA) announced that its phase 3 KOASTAL-2 and KOASTAL-3 studies of navacaprant for major depressive disorder failed to meet primary endpoints, prompting the company to discontinue development of the drug candidate.

The KOASTAL-2 study enrolled 430 patients, while KOASTAL-3 enrolled 422 patients. In KOASTAL-2, patients treated with navacaprant 80 mg showed similar improvement to placebo on the Montgomery-Åsberg Depression Rating Scale at week 6. In KOASTAL-3, navacaprant patients demonstrated numerically lower improvement than placebo patients.

Following the trial results, Neumora will reduce its workforce by approximately 35%, resulting in annualized cost savings of about $10 million. The company

Neumora discontinues navacaprant after phase 3 trials fail primary endpoints

Mon, 15 Jun 2026 08:00:42 -0400

Following the trial results, Neumora will reduce its workforce by approximately 35%, resulting in annualized cost savings of about $10 million. The company

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

WATERTOWN, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases,

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Mon, 15 Jun 2026 08:00:00 -0400

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant

Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease

Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027

Form 4 Neumora Therapeutics, For: May 27 Filed by: Burow Kristina

Fri, 29 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260529/26575836.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Burow Kristina

Fri, 29 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260529/26575836.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Fust Matthew K

Fri, 29 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260529/26575765.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Fust Matthew K

Fri, 29 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260529/26575765.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Piacquad David

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575543.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Piacquad David

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575543.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Halawa Alaa

Fri, 29 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260529/26575529.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Halawa Alaa

Fri, 29 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260529/26575529.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Ho Maykin

Fri, 29 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26575515.html

Form 4 Neumora Therapeutics, For: May 27 Filed by: Ho Maykin

Fri, 29 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260529/26575515.html

Form 8-K Neumora Therapeutics, For: May 27

Fri, 29 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260529/26575051.html

Form 8-K Neumora Therapeutics, For: May 27

Fri, 29 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260529/26575051.html